Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
This is a national, multi center, retrospective observational cohort study that will be carried out by reviewing the medical records of patients with relapsed epithelial ovarian, fallopian tube, or peritoneal cancer treated with olaparib following response to platinum-based chemotherapy.
Relapsed Ovarian Cancers Patients
DRUG: Olaparib
progression free survival (PFS), PFS (days) = date of progression - date of treatment start + 1, through study completion, an average of 1 year|overall Survival (OS), OS (days) = date of death - date of treatment start + 1, through study completion, an average of 1 year|incidence of events of clinical interest, the following events: anemia, thrombopenia, nausea and vomiting, fatigue, myelodysplastic syndrome, upper respiratory infections, diarrhea, decreased appetite, dysgeusia and headache will be formally retrieved from the source documents., through study completion, an average of 1 year
This is a national, multi center, retrospective observational cohort study that will be carried out by reviewing the medical records of patients with relapsed epithelial ovarian, fallopian tube, or peritoneal cancer treated with olaparib following response to platinum-based chemotherapy.